Systemic administration of azithromycin as an adjunct to non-surgical periodontal therapy in generalized stage III and IV, grade C periodontitis- a randomized controlled trial.

School of Dentistry, University of Queensland0 个研究点目标入组 56 人开始时间: 2019年4月10日最近更新: 2023年3月6日

适应症

试验速览

暂无简介。

•a) diagnosis of stage III and IV periodontitis, defined by at least 30% of the sites with probing depth or clinical attachment level (CAL) equal to or greater than 4 mm with bleeding on probing (BOP). Additionally the presence of pocket depth equal to or greater than 6 mm with bleeding on probing on at least 6 sites on a minimum of 3 teeth.
•Grade C periodontitis is further defined by presence of ONE of the following features:
•equal to greater than 2 mm of CAL loss over 5 years,
•% bone loss/age > 1.0,
•destruction exceeds expectation given biofilm deposits, specific clinical patterns suggestive of periods of rapid progression and early onset disease (e.g., molar/incisor pattern),
•smokers equal to greater than 10 cigarettes/day,
•HbA1c equal to or greater than 7.0% in patients with diabetes mellitus
•b. age 25 to 75 years;
•c. At least 16 natural teeth.

•a.use of antimicrobials within 3 months preceding the start of the study;
•b.history of sensitivity to azithromycin or macrolides
•d.prolonged QT interval or history of cardiac arrhythmia or history of myocardial infarction
•e.periodontal debridement in the past 6 months
•f. pregnant women

发起方

School of Dentistry, University of Queensland